spiro[2,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: spiro[2,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione
• 化学式: C₂₀H₂₆O₃
• 分子量: 314.4
• InChiKey: FTWZQYBELWYJGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
  申请人：Emory University

  公开号：US10286113B2

  公开（公告）日：2019-05-14

  The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

  本公开涉及用于骨形成、骨折治疗、骨移植、骨融合、软骨维护和修复的化合物和组合物及其相关方法。在某些实施方案中，本公开涉及包含一种或多种本文公开的化合物的组合物，例如克霉唑、霍诺酚、麦格诺尔、他克莫司、吡美莫司、西罗莫司、依维莫司、西罗莫司、依维莫司、替米考酚酯、螺内酯、氟替卡松、丙酸氟替卡松、糠酸氟替卡松、利奈唑胺、替米沙坦、氯霉素、视黄醇、异维A酸、阿曲汀、依曲替酸、维A酸、维甲酸、替尼泊苷、丝裂霉素 C、阿糖胞苷、地西他滨、长春新碱、长春瑞滨、长春瑞滨、长春瑞滨、瓦鲁比星、多柔比星、达诺比星、表柔比星、依达比星、伊达比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、依达比星、依达比星、米托蒽醌、匹蒽醌、普利霉素、帕唑帕尼、拓扑替康、喜树碱、伊立替康、舒尼替尼、衍生物或其盐，用于骨生长过程。在一个典型的实施方案中，骨移植组合物被植入受试者所需骨生长或增强的部位。
• BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO
  申请人：Boden Scott D.

  公开号：US20140248372A1

  公开（公告）日：2014-09-04

  The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
• Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto
  申请人：Emory University

  公开号：US20160361470A1

  公开（公告）日：2016-12-15

  The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.